Search Results
Diese Website durchsuchen
548 Ergebnisse gefunden mit einer leeren Suche
- Lonza agrees to acquire five Merck KGaA US CDMO facilities to expand advanced biologics manufacturing
Lonza has agreed to acquire five US contract development and manufacturing facilities from Merck KGaA, strengthening its capabilities in advanced biologics, bioconjugation, viral vectors and specialised drug delivery. The definitive agreement announced on 3 November 2026 covers facilities and associated businesses across Missouri, Wisconsin, California and Indiana, with approximately 1,100 employees expected to transfer and Lonza's US CDMO network set to expand from four to nine sites. The acquisition is expected to close in mid-2027 subject to customary conditions, while the companies have described the enterprise valuation using differing approximate currency ranges without confirming a precise transaction price. Field Content Article Type Deals Acquirer Lonza Seller Merck KGaA, Darmstadt, Germany Deal Type Definitive agreement to acquire US CDMO facilities and associated businesses Announcement Date 3 November 2026 Transaction Status Agreed; closing pending Expected Closing Mid-2027 Number of Facilities Acquired Five Geographic Scope United States Facility States Missouri; Wisconsin; California; Indiana Current Lonza US CDMO Sites Four Potential Lonza US CDMO Sites After Closing Nine Employees Expected to Transfer Approximately 1,100 Business Category Contract development and manufacturing organisation Acquired Capability Bioconjugation Additional Capability High-potency payload-linker manufacturing Advanced Therapy Capability Viral-vector manufacturing Drug Delivery Capability Advanced drug-delivery technologies Therapeutic Applications Biologics and advanced therapeutic manufacturing Lonza Valuation Description Low-to-mid triple-digit millions of Swiss francs Seller Valuation Description Mid-triple-digit millions of euros Exact Transaction Price Not disclosed as a single confirmed amount in supplied summary Closing Conditions Subject to customary transaction conditions What Happened Lonza agreed to acquire five US CDMO facilities and associated businesses from Merck KGaA. Why It Matters The acquisition would substantially expand Lonza's US manufacturing footprint and add specialised capabilities supporting complex biologics and advanced therapies. Strategic Rationale Strengthen US-based CDMO capacity, broaden advanced manufacturing services and expand capabilities across the biologics supply chain. Transaction Distinction Definitive acquisition agreement; transaction not yet completed. Key Takeaway Lonza plans to add five US facilities and approximately 1,100 employees, potentially expanding its US CDMO network to nine sites. What to Watch Regulatory approvals, closing conditions, employee transfers, site integration, customer continuity and capacity expansion. Primary Source Lonza Primary Source URL https://www.lonza.com/news/2026-11-03-07-00 Relevant Date 3 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Karyopharm plans Ayrmid merger through Chapter 11 restructuring with $55 million financing commitment
Karyopharm Therapeutics has announced a proposed merger with Ayrmid through a court-supervised Chapter 11 restructuring process, supported by a $55 million additional financing commitment. The restructuring support agreement announced on 2 November 2026 follows Karyopharm's voluntary US bankruptcy filings and outlines a potential combination with Ayrmid under a reorganisation plan that remains subject to court oversight and competing bids. The additional $55 million commitment is intended to support operations during restructuring rather than fund an acquisition purchase price, with the proposed merger expected to close in the first quarter of 2027 if the required approvals and conditions are satisfied. Field Content Article Type Deals Company Karyopharm Therapeutics Proposed Merger Partner Ayrmid Deal Type Proposed merger through Chapter 11 restructuring Announcement Date 2 November 2026 Transaction Status Proposed; not completed Restructuring Framework US Chapter 11 bankruptcy process Bankruptcy Filing Status Voluntary petitions filed Transaction Mechanism Court-supervised reorganisation plan Restructuring Agreement Restructuring support agreement Expected Closing First quarter of 2027 Additional Financing Commitment $55 million Financing Purpose Support operations during restructuring Acquisition Consideration Not confirmed in supplied summary Financial Clarification The $55 million is an operational financing commitment, not a merger purchase price Court Approval Required Competing Bid Process Transaction plan permits competing bids Other Closing Conditions Applicable restructuring and transaction conditions Therapeutic Area Oncology Continuing Development Focus Multiple myeloma; myelofibrosis Commercial Portfolio Details Not specified in supplied summary What Happened Karyopharm filed for Chapter 11 protection and announced a restructuring support agreement contemplating a merger with Ayrmid. Why It Matters The proposed transaction could reshape Karyopharm's ownership and financial structure while supporting continuity of its oncology operations and development programmes. Strategic Rationale Pursue financial restructuring and a potential merger while preserving operational continuity. Transaction Distinction A proposed court-supervised restructuring merger, not a completed acquisition. Key Takeaway Karyopharm's planned Ayrmid combination remains contingent on bankruptcy-court proceedings, competing bids and other closing conditions. What to Watch Court hearings, competing bids, restructuring plan approval, financing availability and the proposed first-quarter 2027 closing. Primary Source Karyopharm Therapeutics SEC filing Primary Source URL https://www.sec.gov/Archives/edgar/data/1503802/000119312526444164/d141618dex992.htm Relevant Date 2 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Rhythm expands LG Chem bivamelagon obesity licence to $855 million and revises royalties
Rhythm Pharmaceuticals has substantially expanded its existing bivamelagon licensing agreement with LG Chem, increasing potential deal consideration to $855 million while securing revised royalty economics across specified MC4R therapies. The amendment announced on 2 November 2026 adds $350 million in fixed payments over four years and a potential $200 million milestone linked to $3 billion in annual global MC4R portfolio sales, raising the agreement's stated potential value from $305 million to $855 million. In exchange, LG Chem's royalties change from low-to-mid-single-digit rates to 1% of global net sales across specified Rhythm MC4R agonists, while Rhythm's separately arranged term-loan facility of up to $750 million represents financing rather than consideration paid under the licence. Field Content Article Type Deals Company Rhythm Pharmaceuticals Licensing Partner LG Chem Deal Type Material amendment to existing exclusive licence agreement Amendment Announcement Date 2 November 2026 Licensed Asset Bivamelagon Drug Class Melanocortin-4 receptor agonist Target MC4R Modality Oral small-molecule therapeutic Administration Route Oral Therapeutic Area Rare obesity disorders Development Status Investigational Original Potential Agreement Value $305 million Revised Potential Agreement Value $855 million Additional Fixed Payments $350 million over four years Additional Contingent Milestone Up to $200 million Milestone Trigger $3 billion in annual global MC4R portfolio sales Previous Royalty Structure Low-to-mid-single-digit royalties Revised Royalty Structure 1% of global net sales across specified Rhythm MC4R agonists Royalty Scope Specified MC4R agonists within Rhythm's portfolio Separate Financing Arrangement Term-loan facility providing access to up to $750 million Financing Clarification The term-loan facility is separate financing and is not licence consideration Geographic Scope Global sales referenced in the amended royalty and milestone terms What Happened Rhythm and LG Chem amended their existing bivamelagon licence to increase fixed and contingent payments while reducing specified royalty obligations. Why It Matters The amendment materially changes the economics of Rhythm's rare obesity portfolio by exchanging increased payment commitments for lower ongoing royalties. Strategic Rationale Improve long-term royalty economics across specified MC4R therapies while maintaining development rights to bivamelagon. Financial Clarification The $855 million represents the amended agreement's stated potential value, including contingent consideration, rather than an upfront payment. Transaction Distinction Amendment to an existing licence; not a newly acquired asset or regulatory approval. Key Takeaway Rhythm committed to additional fixed payments and a potential sales milestone in return for a revised 1% royalty structure. What to Watch Bivamelagon clinical development, MC4R portfolio sales, fixed payment schedules, milestone triggers and future financing needs. Primary Source Rhythm Pharmaceuticals Primary Source URL https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-and-lg-chem-enter-amendment-bivamelagon Relevant Date 2 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- HRV Pharma acquires German Phatebo to enter European finished-dose pharmaceuticals market
India's HRV Pharma has acquired Germany-based Phatebo GmbH, establishing a European platform for finished-dose pharmaceuticals and clinical-trial supply services beyond its existing active pharmaceutical ingredients business. The completed acquisition announced on 3 November 2026 gives HRV Pharma full ownership of Phatebo, a licensed pharmaceutical wholesaler and clinical supply specialist acquired from ZeroStack Corp, while retaining the German company's existing name, management and workforce. Financial consideration was not disclosed, and Phatebo's reported approximately ₹350 crore in 2025 revenue should be understood as a business performance figure rather than the transaction price. Field Content Article Type Deals Acquirer HRV Pharma Acquired Company Phatebo GmbH Seller ZeroStack Corp Deal Type Completed cross-border pharmaceutical acquisition Announcement Date 3 November 2026 Transaction Status Completed Equity Stake Acquired 100% Acquired Company Location Germany Acquirer Country India Geographic Expansion European pharmaceutical market Acquired Business Type Licensed pharmaceutical wholesaler and clinical-trial supply specialist Existing Acquirer Focus Active pharmaceutical ingredients New Business Focus Finished-dose pharmaceutical formulations and clinical supply Acquired Company Operating Name Phatebo GmbH retained Management Continuity Existing management retained Workforce Continuity Existing team retained Subsidiary Status Wholly owned subsidiary of HRV Pharma Reported Acquired Company Revenue Approximately ₹350 crore in 2025 Transaction Consideration Not disclosed Financial Clarification Reported 2025 revenue is not the acquisition purchase price Therapeutic Areas Not specified in supplied summary What Happened HRV Pharma acquired 100% of Phatebo GmbH from ZeroStack Corp to expand into European finished formulations and clinical supply operations. Why It Matters The acquisition provides HRV with an established German pharmaceutical business and a platform for moving beyond API supply into finished-dose products and clinical services. Strategic Rationale Diversify pharmaceutical operations and establish a stronger commercial and supply-chain presence in Europe. Operational Integration Phatebo will continue under its existing name, management and team as an HRV subsidiary. Key Takeaway HRV Pharma has completed a European acquisition that broadens its business beyond APIs, with financial terms undisclosed. What to Watch European market expansion, finished-formulation portfolio development, clinical supply partnerships and post-acquisition integration. Primary Source Business Standard reporting Primary Source URL https://www.business-standard.com/companies/news/hrv-pharma-acquires-german-firm-phatebo-enters-finished-formulations-biz-126110301623_1.html Relevant Date 3 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Teva secures US commercialisation rights to two Samsung Bioepis immunology biosimilars in deal worth up to $420 million
Teva has secured US commercialisation rights to two FDA-approved Samsung Bioepis immunology biosimilars under an agreement worth up to $420 million, expanding its specialty biologics portfolio. The agreement announced on 3 November 2026 covers infliximab-abda, a biosimilar referencing Remicade, and ETICOVO (etanercept-ykro), referencing Enbrel, with Teva committing $50 million upfront subject to conditions and up to $370 million in additional launch and commercial milestones. Samsung Bioepis will retain manufacturing and regulatory responsibilities while the partners share commercial profits, with ETICOVO rights expected to transfer at closing by year-end 2026 and infliximab-abda rights scheduled to transfer in the third quarter of 2027; both products were previously FDA-approved, making this a commercialisation transaction rather than a new regulatory approval. Field Content Article Type Deals Company Teva Pharmaceutical Industries Partner Samsung Bioepis Deal Type US biosimilar licence and commercialisation agreement Announcement Date 3 November 2026 Transaction Status Agreement announced; rights transfers pending Products Covered Two FDA-approved immunology biosimilars Product 1 Infliximab-abda Product 1 Reference Medicine Remicade Product 2 ETICOVO (etanercept-ykro) Product 2 Reference Medicine Enbrel Therapeutic Area Immunology; inflammatory and autoimmune diseases Modality Biosimilar monoclonal antibody and fusion protein therapeutics Maximum Potential Deal Value $420 million Upfront Payment $50 million subject to conditions Additional Milestones Up to $370 million in launch and commercial milestones Profit-Sharing Structure Commercial profits shared between Teva and Samsung Bioepis Commercialisation Responsibilities Teva receives US commercialisation rights Manufacturing Responsibilities Samsung Bioepis retains manufacturing responsibilities Regulatory Responsibilities Samsung Bioepis retains regulatory responsibilities ETICOVO Rights Transfer At closing; expected by the end of 2026 Infliximab-abda Rights Transfer Third quarter of 2027 Previous FDA Approval Years Infliximab-abda: 2017; ETICOVO: 2019 Geographic Scope United States Regulatory Status Both biosimilars previously FDA-approved; no new approvals announced What Happened Teva and Samsung Bioepis entered an agreement granting Teva US commercialisation rights to two existing immunology biosimilars. Why It Matters The transaction strengthens Teva's US biosimilar portfolio and creates additional commercial opportunities in established immunology markets. Strategic Rationale Combine Samsung Bioepis' manufacturing and regulatory capabilities with Teva's US commercial infrastructure. Transaction Distinction Separate from the companies' previously announced six-candidate biosimilar development collaboration. Key Takeaway Teva has agreed to pay up to $420 million for US commercialisation rights, comprising $50 million upfront and up to $370 million in contingent milestones. What to Watch Closing conditions, rights transfers, US launch plans, formulary access, commercial uptake and milestone achievement. Primary Source Teva Pharmaceutical Industries Primary Source URL https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-and-Samsung-Bioepis-Announce-Agreement-to-Commercialize-Two-FDA-Approved-Biosimilars-in-the-U-S-/default.aspx Relevant Date 3 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Novartis terminates BioArctic BrainTransporter neuroscience collaboration after discontinuing antibody programme
Novartis has terminated its neuroscience collaboration with BioArctic following discontinuation of the underlying antibody programme, ending a BrainTransporter licensing arrangement established in August 2025. BioArctic announced on 2 November 2026 that Novartis had ended the option, collaboration and licence agreement involving delivery of an undisclosed antibody using BioArctic's BrainTransporter technology, while stating that the decision was unrelated to the delivery platform itself. BioArctic retains the original $30 million upfront payment and expects to recognise the remaining deferred portion as revenue in 2026, but the termination removes potential future payments from this particular collaboration without affecting the company's other BrainTransporter partnerships. Field Content Article Type Deals Companies Novartis; BioArctic Deal Type Termination of option, collaboration and licence agreement Termination Announcement Date 2 November 2026 Original Agreement Date August 2025 Agreement Status Terminated Technology Platform BioArctic BrainTransporter Technology Focus Antibody delivery to the brain Therapeutic Area Neuroscience Target Programme Undisclosed Novartis antibody programme Programme Status Discontinued by Novartis Reason for Termination Discontinuation of the underlying antibody programme Platform-Related Termination BioArctic stated that the decision was unrelated to BrainTransporter technology Original Upfront Payment $30 million Upfront Payment Retention BioArctic retains the original upfront payment Deferred Revenue Treatment Remaining deferred portion expected to be recognised as 2026 revenue Future Milestone Opportunity Potential future payments under the terminated agreement will no longer be available Original Agreement Headline Value Not independently confirmed in supplied summary Other BrainTransporter Partnerships Unaffected according to BioArctic Geographic Scope Not specified in supplied summary What Happened Novartis terminated its collaboration and licence agreement with BioArctic after discontinuing the antibody programme associated with the partnership. Why It Matters The termination removes a potential neuroscience development and licensing revenue stream while highlighting programme-specific risks in biotechnology partnerships. Financial Impact BioArctic retains the $30 million upfront payment and expects to recognise remaining deferred revenue in 2026, but loses potential future agreement payments. Technology Implications BioArctic attributes the termination to the underlying Novartis programme rather than to its BrainTransporter delivery platform. Transaction Distinction Termination of an existing collaboration; not a newly signed licensing agreement or acquisition. Key Takeaway The Novartis collaboration has ended, but BioArctic retains its upfront payment and continues its other BrainTransporter partnerships. What to Watch BioArctic's 2026 revenue recognition, remaining BrainTransporter partnerships, new licensing opportunities and future platform development. Primary Source BioArctic Primary Source URL https://www.bioarctic.com/en/bioarctic-collaborator-novartis-terminates-agreement/ Relevant Date 2 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Biossil acquires Theriva antibiotic-degrading enzyme portfolio with up to $91 million in milestones
Biossil Labs has acquired Theriva Biologics' antibiotic-degrading enzyme portfolio, including Phase IIb-stage ribaxamase, in an asset transaction carrying up to $91 million in contingent milestones. The completed acquisition announced on 2 November 2026 transfers SYN-004 (ribaxamase), SYN-007 and specified SYN-006 assets to Biossil, which will assume future development and commercialisation responsibilities for programmes targeting antibiotic-associated microbiome disruption and related complications. Theriva received $350,000 upfront at closing and remains eligible for up to $3 million in regulatory milestones, $88 million in sales milestones and low-single-digit royalties subject to a $250 million cap, making the headline $91 million a contingent milestone opportunity rather than the immediate acquisition price. Field Content Article Type Deals Acquirer Biossil Labs Seller Theriva Biologics Deal Type Completed pharmaceutical asset acquisition Announcement Date 2 November 2026 Transaction Status Completed Acquired Portfolio Antibiotic-degrading enzyme programmes Lead Programme SYN-004 (ribaxamase) Lead Programme Development Stage Phase IIb Additional Programme SYN-007 Additional Assets Specified SYN-006 assets Therapeutic Focus Antibiotic-associated microbiome disruption and related complications Modality Antibiotic-degrading enzyme therapeutics Upfront Consideration $350,000 paid at closing Potential Regulatory Milestones Up to $3 million Potential Sales Milestones Up to $88 million Total Potential Milestones Up to $91 million Royalty Terms Low-single-digit royalties Royalty Cap $250 million Development Responsibilities Biossil assumes future development responsibilities Commercialisation Responsibilities Biossil assumes future commercialisation responsibilities Acquisition Scope Specified therapeutic assets; not an acquisition of Theriva Biologics Geographic Scope Not confirmed in supplied summary What Happened Biossil acquired Theriva's antibiotic-degrading enzyme portfolio in a completed asset sale. Why It Matters The acquisition transfers clinical-stage and related enzyme programmes to a new developer pursuing approaches to protect the microbiome from antibiotic-associated disruption. Strategic Rationale Advance antibiotic-degrading enzyme technologies through Biossil's development and commercialisation platform. Financial Clarification The $91 million represents potential regulatory and sales milestones, not upfront acquisition consideration. Key Takeaway Theriva received $350,000 at closing and may earn substantial contingent payments and royalties if Biossil advances and commercialises the acquired assets. What to Watch Ribaxamase development plans, subsequent clinical studies, regulatory milestones, commercialisation progress and royalty-generating sales. Primary Source Theriva Biologics Primary Source URL https://therivabio.com/press_releases/theriva-biologics-announces-sale-of-syn-004-ribaxamase-and-related-antibiotic-degrading-enzyme-portfolio-to-biossil-labs-inc/ Relevant Date 2 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- AGC Biologics expands dual-site pharmaceutical manufacturing contract to more than €500 million
AGC Biologics has expanded a long-term manufacturing agreement with an unnamed global pharmaceutical company to more than €500 million, adding six commercial biologics programmes at its Copenhagen facility. The agreement announced on 3 November 2026 extends an existing five-programme manufacturing relationship at AGC Biologics' Yokohama site in Japan to Copenhagen, Denmark, creating an 11-programme dual-site arrangement encompassing technology transfer, scale-up, validation and commercial drug-substance manufacturing. The expanded contract exceeds €500 million in total value and includes planned regulatory submissions for the two manufacturing locations, although neither the customer's identity nor the incremental financial value of the newly added Copenhagen work was disclosed. Field Content Article Type Deals Company AGC Biologics Customer Undisclosed global pharmaceutical company Deal Type Expanded long-term commercial biologics manufacturing agreement Announcement Date 3 November 2026 Transaction Status Contract expansion announced Total Expanded Contract Value More than €500 million Incremental Contract Value Not disclosed Financial Clarification The €500 million-plus figure represents total expanded contract value, not necessarily incremental new business. Existing Manufacturing Programmes Five programmes Additional Manufacturing Programmes Six programmes Combined Programme Count 11 programmes Existing Manufacturing Site Yokohama, Japan Additional Manufacturing Site Copenhagen, Denmark Manufacturing Arrangement Dual-site commercial biologics manufacturing Product Category Biologics Manufacturing Activities Technology transfer; process scale-up; validation; commercial drug-substance manufacturing Regulatory Activities Planned dual-site regulatory submissions Manufacturing Stage Commercial manufacturing Customer Identity Not disclosed Therapeutic Indications Not disclosed Geographic Scope Denmark and Japan What Happened AGC Biologics expanded an existing manufacturing agreement to include six additional commercial biologics programmes at its Copenhagen facility. Why It Matters The agreement demonstrates substantial demand for commercial biologics manufacturing capacity and extends an established customer relationship across two international production sites. Strategic Rationale Expand manufacturing capacity, support supply continuity and provide geographically diversified commercial production capabilities. Operational Significance The arrangement connects existing Yokohama manufacturing activities with additional Copenhagen programmes and planned regulatory submissions. Key Takeaway AGC Biologics' expanded contract exceeds €500 million in total value, while the incremental value of the expansion remains undisclosed. What to Watch Technology transfer progress, manufacturing validation, regulatory submissions, production ramp-up and future programme additions. Primary Source AGC Biologics Primary Source URL https://www.agcbio.com/news/global-pharmaceutical-company-commits-to-a-dual-site-deal-with-agc-biologics-exceeding-0.5-billion Relevant Date 3 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Pelthos and Castle Creek agree biotechnology merger with up to $300 million in contingent milestone payments
Pelthos Therapeutics and Castle Creek Biosciences have agreed to merge, combining a dermatology portfolio with a fibroblast-based cell and gene therapy platform for serious skin diseases. The proposed transaction, announced on 30 October 2026, would bring Castle Creek's investigational D-Fi programme for dystrophic epidermolysis bullosa into the combined business, with Castle Creek shareholders receiving 5.2 million Pelthos shares representing approximately 32.5% of fully diluted ownership at closing. Additional consideration could include up to 5.8 million shares and as much as $300 million in contingent milestone payments, with closing expected by the end of the first quarter of 2027 subject to customary conditions. Field Content Article Type Deals Companies Pelthos Therapeutics; Castle Creek Biosciences Deal Type Definitive biotechnology merger agreement Announcement Date 30 October 2026 Transaction Status Announced; closing pending Expected Closing By the end of the first quarter of 2027 Therapeutic Area Dermatology; rare genetic skin diseases Combined Portfolio Focus Dermatology products and investigational cell and gene therapies Acquired Technology Platform Fibroblast-based cell and gene therapy Lead Investigational Programme D-Fi Target Indication Dystrophic epidermolysis bullosa Programme Regulatory Status Investigational; no new marketing approval announced Initial Share Consideration 5.2 million Pelthos shares Expected Castle Creek Shareholder Ownership Approximately 32.5% on a fully diluted basis at closing Potential Additional Share Consideration Up to 5.8 million shares Potential Contingent Milestone Payments Up to $300 million Milestone Payment Clarification Contingent consideration; not an upfront cash payment Closing Conditions Subject to customary transaction closing conditions What Happened Pelthos and Castle Creek entered a definitive merger agreement combining dermatology assets with a fibroblast-based cell and gene therapy platform. Why It Matters The merger could broaden the combined company's dermatology portfolio into advanced therapies for serious genetic skin diseases. Strategic Rationale Integrate commercial dermatology capabilities with Castle Creek's investigational cell and gene therapy programmes. Financial Structure Initial equity consideration plus potential additional shares and up to $300 million in contingent milestone payments. Key Takeaway The merger is proposed rather than completed, with significant additional consideration dependent on future milestones. What to Watch Transaction approvals, closing by the first quarter of 2027, D-Fi development progress, integration plans and milestone achievement. Primary Source Pelthos Therapeutics SEC filing Primary Source URL https://ir.pelthos.com/sec-filings/all-sec-filings/content/0001104659-26-120458/tm2628523d2_ex99-1.htm Relevant Date 30 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Supernus and Indivior complete merger to create diversified CNS biopharmaceutical company
Supernus and Indivior have completed a merger of equals, creating a diversified central nervous system biopharmaceutical company with an 11-product portfolio spanning addiction treatment, psychiatry and neurology. The transaction, completed on 2 November 2026, establishes Supernus Inc. as the combined business, with former Indivior shareholders holding approximately 56.5% and former Supernus shareholders holding approximately 43.5% of the company. Under the merger terms, Supernus shareholders received 1.5401 Indivior shares for each share held, while legacy Indivior shareholders received an aggregate $1 billion special cash dividend, with the combined company scheduled to begin trading under the SUPN ticker on 3 November. Field Content Article Type Deals Company Supernus Inc. Merger Parties Supernus Pharmaceuticals; Indivior Deal Type Completed merger of equals Transaction Status Completed Completion Date 2 November 2026 Combined Company Name Supernus Inc. Therapeutic Focus Central nervous system disorders Therapeutic Areas Opioid use disorder; psychiatry; neurology Combined Product Portfolio 11 products Former Indivior Shareholder Ownership Approximately 56.5% Former Supernus Shareholder Ownership Approximately 43.5% Share Exchange Ratio 1.5401 Indivior shares for each Supernus share Special Cash Dividend Aggregate $1 billion to legacy Indivior shareholders Stock Ticker SUPN Expected Trading Commencement 3 November 2026 Geographic Scope Not specified in supplied summary Transaction Valuation Not confirmed in supplied summary What Happened Supernus and Indivior completed a merger of equals to establish a diversified CNS-focused biopharmaceutical company. Why It Matters The combination brings together an 11-product portfolio across addiction medicine, psychiatry and neurology, creating a broader commercial and therapeutic platform. Strategic Rationale Combine complementary CNS portfolios and commercial capabilities within a single biopharmaceutical organisation. Financial Structure Equity exchange with a 1.5401 share exchange ratio and an aggregate $1 billion special cash dividend to legacy Indivior shareholders. Key Takeaway The merger is complete, with former Indivior shareholders owning approximately 56.5% and former Supernus shareholders approximately 43.5% of the combined company. What to Watch Post-merger integration, product portfolio performance, commercial execution, financial guidance and trading under the SUPN ticker. Primary Source Supernus Pharmaceuticals Primary Source URL https://ir.supernus.com/news-releases/news-release-details/supernus-and-indivior-complete-merger-creating-diversified-cns Relevant Date 2 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Zydus completes acquisition of Sterling Biotech fermentation-based API business
Zydus Lifesciences has completed its acquisition of Sterling Biotech's fermentation-based active pharmaceutical ingredients business, expanding its manufacturing capabilities in India. The transaction, completed on 2 November 2026 under a business transfer agreement originally signed in September 2024, includes a manufacturing facility near Vadodara and API operations associated with products such as lovastatin, daunorubicin, doxorubicin and epirubicin. The original agreement specified consideration of ₹84 crore subject to closing adjustments, although the final adjusted transaction amount was not reliably confirmed in the supplied reporting, making the completion and manufacturing expansion the principal verified developments. Field Content Article Type Deals Acquirer Zydus Lifesciences Seller Sterling Biotech Deal Type Active pharmaceutical ingredients business acquisition Transaction Status Completed Completion Date 2 November 2026 Original Agreement Date 17 September 2024 Transaction Structure Business transfer agreement Acquired Business Fermentation-based active pharmaceutical ingredients operations Manufacturing Facility Facility near Vadodara, India Manufacturing Technology Fermentation-based API production Example API Lovastatin Oncology API Examples Daunorubicin; doxorubicin; epirubicin Therapeutic Areas Cardiovascular medicine; oncology Original Agreement Consideration ₹84 crore subject to closing adjustments Final Adjusted Consideration Not reliably confirmed in supplied summary Geographic Scope India Regulatory Status Business acquisition completion; no new drug marketing approval announced What Happened Zydus Lifesciences completed its acquisition of Sterling Biotech's fermentation-based API business under a previously signed business transfer agreement. Why It Matters The acquisition adds fermentation-based API manufacturing capacity and capabilities relevant to established pharmaceutical ingredients, including oncology medicines. Strategic Rationale Expand Zydus' manufacturing infrastructure and strengthen its position in specialised active pharmaceutical ingredients. Transaction History Agreement signed in September 2024 and acquisition completed in November 2026. Financial Clarification The original agreement cited ₹84 crore subject to adjustments; no revised final consideration is asserted. Key Takeaway Zydus has completed a strategic API manufacturing acquisition, adding fermentation capabilities and a facility near Vadodara. What to Watch Facility integration, production capacity, manufacturing investment, regulatory compliance and future API supply expansion. Primary Source Zydus Lifesciences corporate announcement via BazaarWatch Primary Source URL https://bazaarwatch.com/announcement/270004/zydus-lifesciences-limited-general-updates Relevant Date 2 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA tentatively approves Dr. Reddy's first generic injectable lenacapavir for HIV prevention
The FDA has granted tentative approval to Dr. Reddy's generic injectable lenacapavir for HIV prevention, marking a major regulatory milestone for affordable twice-yearly PrEP access in lower-income countries. The generic formulation is intended for HIV pre-exposure prophylaxis in 120 low- and middle-income countries covered by Gilead's voluntary licensing arrangements, with an agreed price of $40 per person annually and development support from Unitaid, Wits RHI and the Clinton Health Access Initiative. Initial supplies are expected before the end of 2026 subject to country-level requirements, while the FDA's tentative approval confirms completion of its scientific review but does not permit immediate generic marketing in the United States. Field Content Article Type Approvals Company Dr. Reddy's Laboratories Product Generic injectable lenacapavir Active Ingredient Lenacapavir Modality Long-acting HIV capsid inhibitor Regulator U.S. Food and Drug Administration Approval Type Tentative approval Approval Announcement Date 2 November 2026 Indication HIV pre-exposure prophylaxis Therapeutic Area HIV prevention Administration Route Injection Dosing Frequency Twice yearly Reference Medicine Developer Gilead Sciences Licensing Framework Gilead voluntary licence Target Markets 120 low- and middle-income countries Agreed Annual Price $40 per person Development Support Unitaid; Wits RHI; Clinton Health Access Initiative Expected Initial Supply Before the end of 2026 subject to country-level requirements US Marketing Status Tentative approval does not authorise immediate generic marketing in the United States Regulatory Significance FDA tentative approval of the first generic injectable lenacapavir for HIV prevention Geographic Scope Licensed lower-income markets; FDA scientific review conducted in the United States What Happened The FDA granted tentative approval to Dr. Reddy's generic injectable lenacapavir for HIV prevention. Why It Matters The decision supports a pathway toward affordable access to long-acting HIV prevention in countries with substantial unmet prevention needs. Regulatory Distinction Tentative approval confirms the FDA's scientific review outcome but is not full US commercial marketing authorisation. Access Significance The agreed $40 annual price and 120-country licence coverage could support broader access to twice-yearly injectable PrEP. Key Takeaway Dr. Reddy's has achieved a significant regulatory milestone for affordable generic lenacapavir, with initial supply dependent on country-specific requirements. What to Watch Country-level authorisations, procurement commitments, manufacturing scale-up, first shipments and HIV prevention programme adoption. Primary Source Clinton Health Access Initiative Primary Source URL https://www.clintonhealthaccess.org/news/us-fda-approves-first-generic-injectable-lenacapavir-for-hiv-prevention/ Relevant Date 2 November 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

